Persistent asthma
Conditions
Interventions
Group 1: Curcuma longa - powdered roots in capsules, oral daily dose of approximately 30 mg/kg/day, twice a day, for 12 months. Total of 24 patients. Assessments each 3 months.
Group 2: Placebo - iden
Drug
B01.650.940.800.575.912.250.618.937.900
Sponsors
Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo
Universidade de Ribeirão Preto
Eligibility
Age
7 Years to 18 Years
Inclusion criteria
Inclusion criteria: Children between 7 and 18 years; with a diagnostic of persistent asthma, mild, moderate or severe, controlled or not.
Exclusion criteria
Exclusion criteria: Allergy to C. longa; parental request; failure to adhere to the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected: Reduction of , classification of disease control , after 12 months , of at least one category , assessed by the method proposed by THOMAS; LEMANSKE; JACKSON, 2011.;Observed: Reduction of , classification of disease control , after 6 months , of at least one category , assessed by the method proposed by THOMAS; LEMANSKE; JACKSON, 2011. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected: Decrease in , forced expiration volume in 1 second (FEV1) , after 12 months , of at least 10% , assessed by pulmonary lung function test (spirometry).;Observed: Decrease in , frequency of nighttime awakenings , after 6 months , of at least one category , assessed by the method proposed by THOMAS; LEMANSKE; JACKSON, 2011.;Observed: Decrease in , frequency of use of short-acting beta-adrenergic agonists , after 6 months , of at least one category , assessed by the method proposed by THOMAS; LEMANSKE; JACKSON, 2011. | — |
Countries
Brazil
Contacts
Public ContactFabio Carmona
Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo
Outcome results
None listed